Clinical Trials on Breast Revision in Colombia

Total 716 results

GlaxoSmithKline

Completed

Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Inflammatory Breast Cancer

Neoplasms, Breast

United States, Canada, Germany, Spain, Taiwan, Belgium, Philippines, Israel, Hong Kong, Thailand, Pakistan, Russian Federation, Italy, Romania, China, France, Peru, United Kingdom, Czech Republic, Australia, Chile, Korea, Republic of and more
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Active, not recruiting

Taxane and Taxane-Induced Peripheral Neuropathy in African American Patients With Stage I-III Breast Cancer

Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic... and other conditions

United States
CorNeat Vision Ltd.

Recruiting

Study to Evaluate the Clinical Safety and Performance of the CorNeat KPro for Treatment of Corneal Blindness

Corneal Opacity | Corneal Disease | Corneal Injuries

France, Canada, Israel, Netherlands
NantCell, Inc.

Completed

QUILT-2.015: A Study of AMG 479 With Exemestane or Fulvestrant in Postmenopausal Women With Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer

Breast Cancer | Metastatic Cancer | Breast Tumors

United States, France, Canada, United Kingdom, Spain, Australia, Germany, Ireland, Switzerland
Spanish Breast Cancer Research Group
Bristol-Myers Squibb; Pfizer; Hoffmann-La Roche

Completed

Fluorouracil, Epirubicin, and Cyclophosphamide Alone or Followed by Paclitaxel for Early Breast Cancer

Breast Cancer

Spain
Hoffmann-La Roche
Chugai Pharmaceutical

Completed

A Study To Evaluate the Efficacy and Safety Of Atezolizumab or Placebo in Combination With Neoadjuvant Doxorubicin + Cyclophosphamide Followed By Paclitaxel + Trastuzumab + Pertuzumab In Early Her2-Positive Breast Cancer (IMpassion050)

Breast Cancer

Korea, Republic of, Canada, Brazil, Germany, Italy, Spain, Japan, Czechia, Poland, United States, Russian Federation, Taiwan
Biotheranostics, Inc.

Active, not recruiting

Breast Cancer Index (BCI) Registry

Breast Cancer

United States
SCRI Development Innovations, LLC
Bristol-Myers Squibb

Completed

A Randomized Trial of Ixempra Versus Taxol in Adjuvant Therapy of Triple Negative Breast Cancer (TITAN)

Breast Cancer

United States, Puerto Rico
Hoffmann-La Roche

Completed

A Study to Compare Subcutaneous (SC) Versus Intravenous (IV) Administration of Herceptin (Trastuzumab) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast Cancer

Breast Cancer

Canada, Germany, Korea, Republic of, Panama, Spain, Turkey, Brazil, Colombia, France, Hungary, Russian Federation, Taiwan, Thailand, Czechia, Italy, Estonia, Peru, South Africa, Sweden, Poland, Israel, Hong Kong, Mexico, Guatemala, Arge... and more
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Active, not recruiting

Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery

Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | Estrogen Receptor-positive Breast Cancer | HER2-negative Breast Cancer | Invasive Lobular Breast Carcinoma | Invasive Ductal Breast Carcinoma

United States, Puerto Rico
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Active, not recruiting

Understanding and Predicting Breast Cancer Events After Treatment (UPBEAT)

Breast Cancer

United States
Radiation Therapy Oncology Group
National Cancer Institute (NCI); NRG Oncology

Completed

Radiation Therapy in Treating Women With Locally Recurrent Breast Cancer Previously Treated With Repeat Breast-Preserving Surgery

Breast Cancer

United States, Canada
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer

Unresectable Breast Carcinoma | Stage IV Breast Cancer AJCC v6 and v7 | Stage III Breast Cancer AJCC v7 | Metastatic Breast Adenocarcinoma | Metastatic HER2-Positive Breast Carcinoma | Recurrent Breast Adenocarcinoma | Recurrent HER2-Positive Breast Carcinoma | Unresectable HER2-Positive Breast Carcinoma

United States, Canada
Pfizer

Completed

Study Of Letrozole With Or Without Palbociclib (PD-0332991) For The First-Line Treatment Of Hormone-Receptor Positive Advanced Breast Cancer

Breast Cancer

Korea, Republic of, United States, Spain, Germany, Ireland, Hungary, Canada, France, Italy, Russian Federation, South Africa, Ukraine
Dana-Farber Cancer Institute

Active, not recruiting

T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial)

Breast Cancer

United States
Hoffmann-La Roche

Active, not recruiting

A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC) (KATE3)

Metastatic Breast Cancer

Korea, Republic of, United Kingdom, Australia, China, Croatia, Finland, France, Norway, Portugal, Slovenia, Canada, Italy, Spain, Colombia, Brazil, Poland, United States, Greece, Turkey, Russian Federation, Philippines
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Active, not recruiting

Palbociclib and Letrozole or Fulvestrant in Treating Patients With Estrogen Receptor Positive, HER2 Negative Metastatic Breast Cancer

HER2/Neu Negative | Estrogen Receptor-positive Breast Cancer | Stage IV Breast Cancer AJCC v6 and v7

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Recruiting

Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab

Anatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Early Stage Triple-Negative Breast Carcinoma

United States, Puerto Rico
NSABP Foundation Inc
National Cancer Institute (NCI)

Completed

Chemotherapy in Treating Women With Breast Cancer That Can Be Surgically Removed

Breast Cancer

United States, Canada
National Cancer Institute (NCI)

Active, not recruiting

Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer

Breast Ductal Carcinoma In Situ | Invasive Breast Carcinoma | Multicentric Breast Carcinoma | Multifocal Breast Carcinoma | Synchronous Bilateral Breast Carcinoma

United States, France, Spain, Canada, Saudi Arabia, Puerto Rico, Korea, Republic of, Ireland, Colombia, Mexico
Spanish Breast Cancer Research Group
Bristol-Myers Squibb

Completed

FAC Versus FAC Plus Weekly Paclitaxel as Adjuvant Treatment of Node Negative High Risk Breast Cancer Patients

Breast Cancer

Spain
Tolmar Inc.

Recruiting

Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer (OVELIA)

Breast Cancer

United States, Mexico, Brazil, Canada, Puerto Rico, Argentina
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Vitamin D and Breast Cancer Biomarkers in Female Patients

Breast Cancer

United States
Lyell Immunopharma, Inc.

Recruiting

A Study to Investigate LYL797 in Adults With Solid Tumors

Advanced Breast Cancer | NSCLC | Non Small Cell Lung Cancer | Triple Negative Breast Cancer | Non-small Cell Lung Cancer | Advanced Lung Carcinoma | Non Small Cell Lung Cancer Metastatic | NSCLC Stage IV | Recurrent Breast Cancer | TNBC - Triple-Negative Breast Cancer | Relapsed Cancer | NSCLC, Recurrent | Recurrent... and other conditions

United States
R-Pharm

Completed

Novel Epothilone Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer

Breast Cancer | Metastases

Belgium, Spain, United States, Argentina, Brazil, Canada, Germany, Peru, Taiwan, United Kingdom, Italy, France, Korea, Republic of, Philippines, Thailand, Mexico, Sweden, China, Hungary, Poland, Greece, Malaysia
Establishment Labs
NAMSA

Recruiting

Motiva Flora® Aesthetic Breast Recon® Clinical Study

Breast Cancer | Mammaplasty | Poland Syndrome

Spain, Belgium, Colombia, Costa Rica
National Cancer Institute (NCI)

Recruiting

Radiation Therapy With or Without Olaparib in Treating Patients With Inflammatory Breast Cancer

Breast Inflammatory Carcinoma

United States, Canada, Puerto Rico
AstraZeneca

Active, not recruiting

Comparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing After Previous Endocrine Therapy. (CONFIRM)

Breast Cancer

Belgium, Spain, Italy, United States, Brazil, Czechia, Russian Federation, Chile, Slovakia, Hungary, India, Ukraine, Venezuela, Colombia, Poland, Malta, Mexico
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Quality of Life, Employment, and Informal Care Costs in Women Who Are Receiving Chemotherapy for Breast Cancer

Breast Carcinoma

United States
AstraZeneca

Active, not recruiting

A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer. (FALCON)

Hormone Receptor Positive Breast Cancer

Canada, Spain, United States, Romania, Taiwan, Italy, Brazil, Peru, Russian Federation, China, Czechia, Ukraine, South Africa, Japan, Poland, Mexico, United Kingdom, Argentina, Slovakia, Turkey
University Health Network, Toronto
The Hospital for Sick Children; Alberta Children's Hospital; British Columbia... and other collaborators

Not yet recruiting

Visual Telerehabilitation in Children, Adolescents and Young Adults With Hemianopsia Consecutive to a Brain Tumour (HHREHAB)

Hemianopsia

Canada
Puma Biotechnology, Inc.

Completed

A Study of Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer Who Have Received Two or More Prior HER2 Directed Regimens in the Metastatic Setting (NALA)

HER2+ Metastatic Breast Cancer (MBC)

United States, Canada, Spain, Singapore, Korea, Republic of, Taiwan, United Kingdom, Israel, Australia, Japan, Hong Kong, Finland, Ireland, Italy, France, Portugal, Germany, Sweden, Belgium, Brazil, Czechia, Switzerland, Argentina, Au... and more
Novartis Pharmaceuticals

Completed

Continued Efficacy and Safety of Zoledronic Acid (q 4 Wks vs. q 12 Wks) in the 2nd Year of Treatment in Patients With Bone Metastases From Breast Cancer

Breast Cancer

United States
National Cancer Institute (NCI)
NCIC Clinical Trials Group; Cancer and Leukemia Group B; North Central Cancer... and other collaborators

Active, not recruiting

Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial) (TAILORx)

Hormone Receptor Positive | Stage IA Breast Cancer AJCC v7 | Stage IB Breast Cancer AJCC v7 | Stage IIA Breast Cancer AJCC v6 and v7 | Stage IIB Breast Cancer AJCC v6 and v7 | Stage IIIB Breast Cancer AJCC v7 | Breast Adenocarcinoma

United States, Canada, Australia, Puerto Rico, New Zealand, Ireland, Peru, United Kingdom
Hoffmann-La Roche

Completed

A Study Evaluating Pertuzumab (Perjeta) Combined With Trastuzumab (Herceptin) and Standard Anthracycline-based Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer (BERENICE)

Breast Cancer

United States, Canada, Denmark, France, Italy, Poland, Portugal, Spain, United Kingdom, Norway, Germany, Mexico
Sopherion Therapeutics

Unknown

Trial of Myocet in Metastatic Breast Cancer

Breast Cancer

Canada, Spain, United States, United Kingdom, Poland, Germany, India, Italy, Argentina, Portugal, Russian Federation
Hoffmann-La Roche

Recruiting

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer

Belgium, Korea, Republic of, United States, Canada, China, Italy, France, Finland, Brazil, Australia, Argentina, Hong Kong, Portugal, Spain, Taiwan, India, Costa Rica, Israel, Thailand, Germany, New Zealand, Poland, Chile, Colombia, Gua... and more
AstraZeneca
Merck Sharp & Dohme LLC; Myriad Genetic Laboratories, Inc.

Active, not recruiting

Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations. (OlympiAD)

Breast Cancer Metastatic | BRCA 1 Gene Mutation | BRCA 2 Gene Mutation

Italy, Spain, United States, Czechia, Romania, France, Korea, Republic of, United Kingdom, Hungary, Japan, Peru, Poland, Russian Federation, Turkey, China, Taiwan, Bulgaria, Switzerland, Mexico
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S9832: Effectiveness of Telephone Counseling By Breast Cancer Survivors on the Well-Being of Women With Recurrent Breast Cancer

Breast Cancer | Psychosocial Effects of Cancer and Its Treatment

United States, Canada
Novartis Pharmaceuticals

Active, not recruiting

Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer (AMALEE)

Breast Cancer

United States, South Africa, Austria, Hungary, Germany, Czechia, France, Russian Federation, Thailand, Belgium, Bulgaria, Lithuania, Jordan, Sweden, Finland, Peru, Colombia, Portugal, Canada, Brazil, India, Argentina, Costa Rica
AstraZeneca

Recruiting

A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy (CAMBRIA-1)

Breast Cancer, Early Breast Cancer

United States, Canada, United Kingdom, China, Argentina, Australia, Hungary, Netherlands, Korea, Republic of, France, Germany, Italy, Belgium, Bulgaria, India, Mexico, Spain, Vietnam, Colombia, Japan, Peru, Brazil, Malaysia, Taiwan, Tha... and more
NSABP Foundation Inc
Hoffmann-La Roche; Genentech, Inc.

Active, not recruiting

Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or Placebo

Triple Negative Breast Cancer

United States, Canada
Hoffmann-La Roche

Completed

A Study of Trastuzumab Emtansine in Comparison With Treatment of Physician's Choice in Participants With HER2-positive Breast Cancer Who Have Received at Least Two Prior Regimens of HER2-directed Therapy (TH3RESA)

Breast Cancer

Belgium, Israel, Spain, Sweden, United States, Switzerland, Russian Federation, Czech Republic, France, Canada, Germany, Korea, Republic of, Australia, Hungary, Thailand, United Kingdom, Italy, Brazil, Slovakia, Poland, India, Norway
AstraZeneca

Active, not recruiting

A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease (SERENA-4)

ER-Positive HER2-Negative Breast Cancer

Austria, Belgium, France, Germany, Italy, United Kingdom, United States, Canada, India, Taiwan, Russian Federation, Korea, Republic of, Hungary, Japan, Mexico, Turkey, China, Malaysia, Spain, Czechia, Portugal, Poland, Norway, Bulgaria, Slovaki... and more
AstraZeneca
Daiichi Sankyo Company, Limited 3-5-1 Nihonbashihoncho, Chuo-ku, Tokyo

Active, not recruiting

Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer (DB-06)

Advanced or Metastatic Breast Cancer

United States, Belgium, Canada, Denmark, France, Italy, Spain, Hungary, Poland, Taiwan, Russian Federation, Germany, Korea, Republic of, Brazil, Japan, Mexico, United Kingdom, China, Israel, Austria, Australia, Saudi Arabia, Netherl... and more
National Cancer Institute (NCI)

Active, not recruiting

Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer

Invasive Breast Carcinoma | Triple-Negative Breast Carcinoma | Stage I Breast Cancer AJCC v7 | Stage II Breast Cancer AJCC v6 and v7 | Stage III Breast Cancer AJCC v7 | Stage 0 Breast Cancer AJCC v6 and v7

United States, Canada, Puerto Rico
Eli Lilly and Company

Available

Named Patient Use Program to Provide Abemaciclib (LY2835219) for the Treatment of Metastatic Breast Cancer

Metastatic Breast Cancer

Australia, Canada, Egypt, India, Italy, Korea, Republic of, Malaysia, Singapore, South Africa, Spain, Switzerland, Taiwan, Thailand, United Kingdom
US Oncology Research
Sanofi

Completed

TAC Versus TC for Adjuvant Breast Cancer

Breast Cancer

United States
NSABP Foundation Inc
National Cancer Institute (NCI)

Completed

Surgery to Remove Sentinel Lymph Nodes With or Without Removing Lymph Nodes in the Armpit in Treating Women With Breast Cancer

Breast Cancer

Canada, United States, Puerto Rico
Canadian Cancer Trials Group
Alliance for Clinical Trials in Oncology; NRG Oncology; Eastern Cooperative Oncology... and other collaborators

Recruiting

Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer (TAILOR RT)

Breast Cancer

United States, Canada

Clinical Trials on Breast Revision in Colombia

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Philippines

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations